Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2624-2630

  McKillop, Aine M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATOGRAPHY; CLINICAL MEDICINE; DIABETES MELLITUS; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLYCEMIC CONTROL; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MASS SPECTROMETRY; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ELECTROPHORESIS; BLOOD; GENETIC PREDISPOSITION; GENETICS; GENOMICS; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLIC SYNDROME X; METABOLISM; OXIDATIVE STRESS;

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HLA ANTIGEN CLASS 2; INSULIN;

ADIPOKINES; ALANINE TRANSAMINASE; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GAMMA-GLUTAMYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HEMOGLOBIN A, GLYCOSYLATED; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; INSULIN; METABOLIC SYNDROME X; METABOLOMICS; OXIDATIVE STRESS;

EID: 84858419687     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0837     Document Type: Review

References (60)

1. Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS ONE 2010;5:e10538
2. Li LO, Hu YF, Wang L, Mitchell M, Berger A, Coleman RA. Early hepatic insulin resistance in mice: a metabolomics analysis. Mol Endocrinol 2010;24:657-666
3. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58:2429-2443
4. Meisinger C, Löwel H, HeierM, Schneider A, Thorand B; KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetesmellitus inmen andwomen from the general population. J Intern Med 2005;258:527-535 (Pubitemid 41705393)
5. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006;22:437-443 (Pubitemid 44774047)
6. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 2008;51:926-940
7. Kolberg JA, Jørgensen T, Gerwien RW, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009;32:1207-1212
8. Salomaa V, Havulinna A, Saarela O, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 2010;5:e10100
9. Christ A, Evers S, Krapfenbauer K, Sebokova E. Pancreatic polypeptide as target/marker of beta cell failure.US patent 2009/0215069.27 August 2009
10. Amrein K, Berndt P, Evers S, Foster S, Fountoulakis M, Sebokova E. Fibronectin as target/marker for insulin resistance. International patent WO/2007/06278.7 June 2007
11. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767
12. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288-1299
13. Sandhu MS. Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 2005;9:44-54
14. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33:2153-2163
15. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta 2004;350:201-209 (Pubitemid 39458264)
16. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 2002;324:61-71 (Pubitemid 35245496)
17. Lindsay JR, McKillop AM, Mooney MH, O'Harte FPM, Bell PM, Flatt PR. Demonstration of increased concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia 2003;46:475-478 (Pubitemid 36577789)
18. Rittenhouse J, Koda J, Fineman M, Percy A. Glycosylated amylins. International patent WO/1997/035600. 2 October 1997
19. Cohen MP. Monoclonal antibodies against glycated low density lipoprotein. US patent 5,494,791. 27 February 1996
20. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38 (Pubitemid 36410972)
21. Sargeant LA, Wareham NJ, Bingham S, et al. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer - Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 2000;23:726-732 (Pubitemid 30414183)
22. Zhao G, Ford ES, Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among U.S. adults without physician-diagnosed diabetes: NHANES, 2003-2006.DiabetesCare 2010;33:344-347
23. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
24. Koyama H, Yamamoto H, Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2007;2:331-339
25. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med 2010;27:1004-1011
26. Freeman DJ,Norrie J,Caslake MJ, et al.;West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-1600 (Pubitemid 34826630)
27. Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 2005;54:2932-2938 (Pubitemid 41401089)
28. Herder C, Brunner EJ, RathmannW, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: theWhitehall II study. Diabetes Care 2009;32:421-423
29. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137 (Pubitemid 34438360)
30. Song Y, Manson JE, Tinker L, et al. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes 2007;56:1898-1904 (Pubitemid 47025455)
31. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008;31:995-1000
32. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589
33. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323
34. Scott LJ,Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345 (Pubitemid 46871655)
35. Sandhu MS, Weedon MN, Fawcett KA, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007;39:951-953 (Pubitemid 47185173)
36. Winckler W, Weedon MN, Graham RR, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007;56:685-693 (Pubitemid 46348464)
37. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638-645 (Pubitemid 351601209)
38. Saxena R, Hivert MF, Langenberg C, et al; GIANT consortium; MAGIC investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42:142-148
39. Salonen JT, Uimari P, Aalto JM, et al. Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. Am J Hum Genet 2007;81:338-345 (Pubitemid 47236080)
40. Zeggini E, Weedon MN, Lindgren CM, et al Wellcome Trust Case Control Consortium (WTCCC). Replication of genome- wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-1341 (Pubitemid 46871654)
41. Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009;41:1110-1115
42. Soranzo N, Sanna S, Wheeler E, et al.; WTCCC. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-3239
43. Schleinitz D, Tönjes A, Böttcher Y, et al. Lack of significant effects of the type 2 diabetes susceptibility loci JAZF1, CDC123/CAMK1D,NOTCH2, ADAMTS9, THADA, and TSPAN8/LGR5 on diabetes and quantitative metabolic traits. Horm Metab Res 2010;42:14-22
44. Boraska V, Rayner NW, Groves CJ, et al. Large-scale association analysis of TNF/LTA gene region polymorphisms in type 2 diabetes. BMC Med Genet 2010;11:69
45. Arora P, Garcia-Bailo B, Dastani Z, et al. Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes. BMC Med Genet 2011;12:95
46. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, Hattersley AT. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34:1860-1862
47. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS ONE 2011;6:e16957
48. Erlich H, Valdes AM, Noble J, et al.; Type 1 Diabetes Genetics Consortium. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008;57:1084-1092
49. Varney MD, Valdes AM, Carlson JA, et al.; Type 1 Diabetes Genetics Consortium. HLA DPA1, DPB1 alleles and haplotypes contribute to the risk associated with type 1 diabetes: analysis of the type 1 diabetes genetics consortium families. Diabetes 2010;59:2055-2062
50. Pugliese A, Gianani R, Moromisato R, et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patientswith IDDM. Diabetes 1995;44:608-613
51. Steck AK, Armstrong TK, Babu SR, Eisenbarth GS; Type 1 Diabetes Genetics Consortium. Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes 2011;60:1045-1049
52. Noble JA, Martin A, Valdes AM, et al. Type 1 diabetes risk for human leukocyte antigen (HLA)-DR3 haplotypes depends on genotypic context: association of DPB1 and HLA class I loci among DR3- and DR4-matched Italian patients and controls. Hum Immunol 2008;69:291-300
53. Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol 2005;66:301-313 (Pubitemid 40395251)
54. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem 2011;57:176-185
55. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-183 (Pubitemid 14184705)
56. Concannon P, Chen WM, Julier C, et al.; Type 1 Diabetes Genetics Consortium. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 2009;58:1018-1022
57. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004;36:337-338 (Pubitemid 38437254)
58. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-707
59. Concannon P, Onengut-Gumuscu S, Todd JA, et al.; Type 1 Diabetes Genetics Consortium. A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. Diabetes 2008;57:2858-2861
60. Guo D, Li M, Zhang Y, et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004;36:837-841 (Pubitemid 39014100)